Диссертация (1139537), страница 46
Текст из файла (страница 46)
– Vol. 34, № 10. – P. 500–510.193. Ajjan R.A. Cardiovascular disease prevention in patients with type 2 diabetes: Therole of oral anti-diabetic agents / R.A. Ajjan, P.J. Grant // Diab. Vasc. Dis. Res. –2006. – Vol. 3, № 3. – P. 147–158.194. Alberti K.G. The metabolic syndrome – a new world-wide definition / K.G. Alberti,P. Zimmet, J. Shaw // Lancet. – 2005. – Vol. 366. – P. 1059–1062.195. Alexandratou E. Human fibroblast alterations induced by low power laserirradiation at the single cell lever using confocal microscopy / E. Alexandratou, D.Yova, P.
Handris // Photochemical and Photobiological Sciences. – 2003. – Vol. 1,№ 8. – P. 547–552.259196. All-cause mortality associated with specific combinations of the metabolicsyndrome according to recent definitions / L. Guize [et al.] // Diabetes Care. – 2007.– Vol. 30. – P. 2381–2387.197. Américo Manuel Da Costa Figueiredo / B.I. Roque [et al.] // J. Clin. Anesthet.Dermatol. – 2016. – Vol. 9, № 6. – P. 36–43.198. An Epidemiological Study on Trigger Factors and Quality of Life in PsoriaticPatients / A. Xhaja [et al.] // Mater.
Sociomed. – 2014. – Vol. 26, № 3. – P. 168–171.199. Anti-inflammatory and analgesic effects of low-level laser therapy on thepostoperative healing process / H.S. Fabre [et al.] // J. Phys. Ther. Sci. – 2015. –Vol. 27. – P. 1645–1648.200. Antioxidant status in patients with psoriasis / H. Nemati [et al.] // Cell Biochem.Funct. – 2014. – Vol. 32, № 3. – P. 268–273.201.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treatnail and scalp psoriasis: Results of 2 phase III randomized, controlled trials(ESTEEM 1 and ESTEEM 2) / P. Rich [et al.] // J. Am. Acad. Dermatol. – 2016. –Vol. 74. – P. 134–142.202. Armstrong A.W. Is tonsillectomy a therapeutic option for plaque-type psoriasis? /A.W. Armstrong, A.G. Florek // J.
Am. Acad. Dermatol. – 2015. – Vol. 73, № 4. –e155.203. Armstrong A.W. Psoriasis and risk of diabetes mellitus: a systematic rewiew andmeta-analysis / A.W. Armsrong, C.T. Harskamp, E.J. Armstrong // JAMADermatol. – 2013. – Vol. 149. – P. 84–91.204. Ashmarin I.P. [et al.] // Regulatory Peptides. – 2000. – Vol. 89. – P. 51.205. Associated comorbidities in psoriasis and inflammatory bowel disease / A.M.Binus [et al.] // J. Eur. Acad. Dermatol. Venerol.
– 2012. – Vol. 26. – P. 644–650.206. Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia inPatients with Psoriasis Vulgaris / M. Coban [et al.] // Ann. Dermatol. – 2016. –Vol. 28, № 1. – P. 74–79.260207. Association of cutaneous mast cells and sensory nerves with psychic stress inpsoriasis / I.T. Harvima [et al.] // Psychother. Psychosom. – 1993. – Vol. 60, № 3–4. – P.
168–176.208. Avshalumov K. Psoriasis: What Has Failed and Why / K. Avshalumov, A.Larian, N.F. Fernandes // J. of Psoiasis and Psoriatic Arthritis. – 2018. – Vol. 17a,№ 1. – Р. 63-69.209. Barks J.L. TNF-α and IL-4 synergistically increase vascular cell adhesionmolecule-1 expression in cultured vascular smooth muscle cells / J.L.
Barks, J.J.McQuillan, F.J. Iademarco // Immunol. – 1997. – Vol. 159. – P. 4532–4538.210. Barolet D. Light–emitting diodes (LEDs) in dermatology / D. Barolet // Semin.Cutan. Med. Surg. – 2008. – Vol. 27, № 4. – P. 227–238.211. Baudrand R. Cortisol dysregulation in obesity-related metabolic disorders / R.Baudrand, A. Vaidya // Curr. Opin. Endocrinol. Diabetes Obes. – 2015.
– Vol. 22,№ 3. – P. 143–149.212. Biphasic dose response in low level light therapy – an update / Y.Y. Huang // DoseResponse. – 2011. – Vol. 9, № 4. – P. 602–618.213. Björntorp P. The metabolic syndrome – a neuroendocrine disorder? / P. Björntorp,R. Rosmond // Br. J. Nutr.
– 2000. – Vol. 83, Suppl. 1. – P. 49-57.214. Blüher S. Leptin in humans: lessons from translational research / S. Blūher // Am.J. Clin. Nutr. – 2009. – Vol. 89, № 3. – P. 991–997.215. Boden-Albala B. Metabolic syndrome and ischemic stroke risk: NorthernManhattan / B. Boden-Albala, R.L. Sacco, H.S.-Lee // Stroke. – 2008. – Vol. 39,№ 1. – P.
30–35.216. Body mass index, waist circumference, body adiposity index, and risk for type 2diabetes in two populations in Brazil: general and Amerindian / R.O. Alvim [et al.]// PLoS One. – 2014. – Vol. 9, № 6. – e100223.217. Bouguéon K. Depression and psoriasis / K. Bouguéon, L. Misery // Ann. Dermatol.Venereol. – 2008. – Vol. 135, Suppl. 4. – P.
254–258.261218. Briganti S. Antioxidant activity, lipid peroxidation and skin diseases. What's new /S. Briganti, M. Picardo // J. Eur. Acad. Dermatol. Venereol. – 2003. – Vol. 17, №6. – P. 663–639.219. Burkett P.R. IL-17 Blockade in Psoriasis / P.R. Burkett, V.K. Kuchroo // Cell. –2016. – Vol. 167, № 7. – P. 1669.220. Calderhead R.G. Low Level Light Therapy with Light–Emitting Diodes for theAging Face / R.G. Calderhead, D.B.
Vasily // Clin. Plast. Surg. – 2016. – Vol. 43,№ 3. – P. 541–550.221. Campbell A. The experience of having psoriasis through the lens of theInternational Classification of Functioning, Disability and Health (ICF) / A.Campbell, C. Hocking, W.J. Taylor // Australas J. Dermatol. – 2014. – Vol. 55, №4.
– P. 241–249.222. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: asystematic literature review / C. Horreau [et al.] // J. Eur. Acad. Dermatol.Venereol. – 2013. – Vol. 27, Suppl. 3. – P. 12–29.223. Chen Y. Psoriasis idependently associated with hyperleptinemia contributing tometabolic syndrome / Y. Chen, C. Wu, J. Shen //Arch. Dermatol. – 2008. – Vol.144.
– P. 1571–1575.224. Choy E. T cells in psoriatic arthritis / E. Choy // Curr. Rheumatol. Rep. – 2007. –Vol. 9, № 6. – P. 437–441.225. Christophers E. Psoriasis – epidemiology and clinical spectrum / E. Christophers //Clin. Exp. Dermatol. – 2001. – Vol. 26, № 4. – P. 314–320.226. Christophers E. The immunopathology of psoriasis and biologic immunotherapy /E. Christophers // J.
Am. Acad. Dermatol. – 2003. – Vol. 49. – P. 44–50.227. Clark M. Metabolic Effects of Obesity and Its Interaction with Endocrine Diseases/ M. Clark, M. Hoenig // Vet. Clin. North Am. Small Anim. Pract. – 2016. – № 11.– P. 30020–30021.228. Cloote H. Psoriasis / H. Cloote // Nurs. Stand. – 2000. – Vol.
14 (45). – P. 47–55.262229. Cohen B.E. Psoriasis and the Risk of Depression in the US Population: NationalHealth and Nutrition Examination Survey 2009-2012 / B.E. Cohen, K.J. Martires,R.S. Ho // JAMA Dermatol. – 2016. – Vol. 152, № 1. – P. 73–79.230. Coimbra S. The triad psoriasis-obesity-adipokine profile / S. Coimbra, C. Catarino,A. Santos–Silva // J. Eur.
Acad. Dermatol. Venereol. – 2016. – Vol. 30, № 11. – P.1876–1885.231. Concomitant Sleep Disorders Significantly Increase the Risk of CardiovascularDisease in Patients with Psoriasis / H.Y. Chiu [et al.] // PLoS One. – 2016. – Vol.11, № 1. – e0146462.232. Correia B. Obesity: a key component of psoriasis / B. Correia, T.
Torres // ActaBiomed. – 2015. – Vol. 86, № 2. – P. 121–129.233. Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolicsyndrome. Preliminary report / M.J. Brito-Luna [et al.] // Cytokine. – 2016. – Vol.85. – P. 130–136.234. Crosstalk between skin inflammation and adipose tissue-derived products:pathogenic evidence linking psoriasis to increased adiposity / A. Chiricozzi [et al.]// Expert Rev. Clin. Immunol. – 2016.
– Vol. 12, № 12. – P. 1299–1308.235. Dandona P. Metabolic syndrome: a comprehensive perspective based oninteractions between obesity and inflammation / P. Dandona, A. Aljada, A.Chaudhuri // Circulation. – 2005. – Vol. 111. – P. 1448–1454.236. Dashchuk A.M. Complex treatment of the pro- and antioxidant system disorders inpatients with psoriasis / A.M. Dashchuk, E.V. Iakovleva // Lik. Sprava.
– 2003. –№ 2. – P. 60–63.237. Definition of treatment goals for moderate to severe psoriasis: a Europeanconsensus / U. Mrowietz [et al.] // Arch. Dermatol. Res. – 2011. – Vol. 303. – P.1–10.238. Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients WithPsoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables:A Prospective, Cross-Sectional Study From Lahore, Pakistan / A.R. Khawaja [etal.] // Prim. Care Companion CNS Disord. – 2015. – Vol. 17, № 3. – P. 25.263239.
DoganP.Superoxidedismutaseandmyeloperoxidaseactivityinpolymorphonuclear leukocytes, and serum ceruloplasmin and copper levels, inpsoriasis / P. Dogan, U. Soyuer, G. Tanrikulu // Br. J. Dermatol. – 1989. – Vol.120. – P. 239–244.240. Dynamic frequency of CD4+CD25+Foxp3+Treg cells in Psoriasis vulgaris / L.Chen [et al.] // J.
Dermatol. Sci. – 2008. – Vol. 51, № 3. – P. 200–203.241. Effect of peptide semax on synaptic activity and short–term plasticity ofglutamatergic synapses of co–cultured dorsal root ganglion and dorsal hornneurons / M.S. Shypshyna [et al.] // SA Fiziol. Zh. – 2015. – Vol. 61, № 4. – P.48–55.242. Effect of semax and its c-terminal fragment pro-gly-pro on the expression of vegffamily genes and their receptors in experimental focal ischemia of the rat brain /E.V. Medvedeva [et al.] // J. of Molecular Neuroscience. – 2013. – Vol.
49. № 2. –С. 328–333243. Elevated odds of metabolic syndrome in psoriasis: a population-based study of ageand sex differences / K. Danielsen [et al.] // Br. J. Dermatol. – 2015. – Vol. 172, №2. – P. 419–427.244. Erikci E.M. Lipid signaling and lipotoxicity in metabolic inflammation: indicationsfor metabolic disease pathogenesis and treatment / E.M. Erikci, G.S. Hotamisligil// J. Lipid. Res.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
